Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187025 | 0.86 | LMNA (0.44) | LMNA | |
| SCHEMBL8523741 | 0.80 | LMNA (0.39) | LMNA | |
| SCHEMBL187026 | 0.75 | — | — | |
| SCHEMBL4154811 | 0.75 | TSHR (0.35) | SOAT1 | |
| SCHEMBL9781203 | 0.75 | — | — | |
| SCHEMBL4645074 | 0.75 | — | — | |
| SCHEMBL8586196 | 0.73 | ALDH1A1 (0.36) | LMNA | |
| SCHEMBL20302569 | 0.73 | ALDH1A1 (0.38) | LMNA | |
| SCHEMBL7509907 | 0.72 | LMNA (0.44) | LMNA | |
| SCHEMBL11325929 | 0.71 | TSHR (0.32) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11957760-B2 | Folate receptor targeted nanoparticle drug conjugates and uses thereof | ELUCIDA ONCOLOGY, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4275758-A2 | METHODS OF FUNCTIONALIZING NANOPARTICLES | Elucida Oncology, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4257156-A2 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023178299-A1 | PRODRUGS OF GANAXOLONE | MARINUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11744897-B2 | Folate receptor targeted nanoparticle drug conjugates and uses thereof | ELUCIDA ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-4106820-B1 | METHODS OF FUNCTIONALIZING NANOPARTICLES | ELUCIDA ONCOLOGY INC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4103236-B1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-8772335-B2 | Adamantyl derivatives as therapeutic agents | WOMAN & INFANTS' HOSPITAL OF RHODE ISLAND (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140121186-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | CHIMERIX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8614200-B2 | Compounds, compositions and methods for treating ocular conditions | CHIMERIX, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130143962-A1 | Adamantyl Derivatives as Therapeutic Agents | WOMEN & INFANTS' HOSPITAL OF RHODE ISLAND (US) | 2013-06-06 | — | — | US | disclosed |
| US-20120165295-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | CHIMERIX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012074980-A2 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISORDERS AND LIVER DISORDERS USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2011011519-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OCULAR CONDITIONS | CHIMERIX, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010141690-A2 | INDANE ANALOGS AND USE AS PHARMACEUTICAL AGENTS AND PROCESS OF MAKING | DARA BIOSCIENCES, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100297079-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | CHIMERIX, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135520-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | CHIMERIX, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121186-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | EYA3, EYA2, PDE6C | LMNA 2085/4885SOAT1 1213/4885 |
| US-11957760-B2 | Folate receptor targeted nanoparticle drug conjugates and uses thereof | FOLR1, FOLR2, DHFR | LMNA 3136/4885SOAT1 2652/4885 |
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | LMNA 3136/4885SOAT1 2652/4885 |
| US-20120165295-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | EYA3, EYA2, PDE6C | LMNA 2085/4885SOAT1 1213/4885 |
| US-20130143962-A1 | Adamantyl Derivatives as Therapeutic Agents | MCL1, TOP2A, TP53 | LMNA 2593/4885SOAT1 2189/4885 |
| US-20100297079-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION | HAVCR2, EIF2AK2, OAT | LMNA 1914/4885SOAT1 1354/4885 |
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | LMNA 3136/4885SOAT1 2652/4885 |
| US-11744897-B2 | Folate receptor targeted nanoparticle drug conjugates and uses thereof | FOLR1, FOLR2, DHFR | LMNA 3136/4885SOAT1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.